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Abstract
Background: There is an urgent need to develop new, safe and effective treatments for human African trypanosomiasis
(HAT) because current drugs have extremely poor safety profiles and are difficult to administer. Here we report the
discovery of 2,4-diaminopyrimidines, exemplified by 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1-
carboxylic acid phenylamide (SCYX-5070), as potent inhibitors of Trypanosoma brucei and the related trypanosomatid
protozoans Leishmania spp.
Methodology/Principal Findings: In this work we show that loss of T. brucei viability following SCYX-5070 exposure was
dependent on compound concentration and incubation time. Pulse incubation of T. brucei with SCYX-5070 demonstrates
that a short period of exposure (10–12 hrs) is required to produce irreversible effects on survival or commit the parasites to
death. SCYX-5070 cured an acute trypanosomiasis infection in mice without exhibiting signs of compound related acute or
chronic toxicity. To identify the molecular target(s) responsible for the mechanism of action of 2,4-diaminopyrimidines
against trypanosomatid protozoa, a representative analogue was immobilized on a solid matrix (sepharose) and used to
isolate target proteins from parasite extracts. Mitogen-activated protein kinases (MAPKs) and cdc2-related kinases (CRKs)
were identified as the major proteins specifically bound to the immobilized compound, suggesting their participation in the
pharmacological effects of 2,4-diaminopyrimidines against trypanosomatid protozoan parasites.
Conclusions/Significance: Results show that 2,4-diaminopyrimidines have a good in vitro and in vivo pharmacological
profile against trypanosomatid protozoans and that MAPKs and CRKs are potential molecular targets of these compounds.
The 2,4-diminipyrimidines may serve as suitable leads for the development of novel treatments for HAT.
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Introduction
Human African trypanosomiasis (HAT) or sleeping sickness is
caused by the trypanosomatid protozoan parasite Trypanosoma
brucei. The two main trypanosome species that cause HAT are T.
b. gambiense and T. b. rhodesiense. An estimated 50 million people in
more than 20 sub-Saharan African countries are at risk of HAT.
Although the number of new cases of HAT have been declining
steadily over the years, approximately 10,000 cases were reported
in 2009 [1]. Trypanosome parasites are transmitted to humans
through a bite from the tsetse fly. When left untreated,
trypanosomes invade the central nervous system (CNS) causing a
second stage of the disease (stage 2) which leads to coma and
death.
Current treatment options for HAT are very limited and not
ideal due to toxicity or lengthy parenteral administration. During
the first stage (stage 1) of the disease when parasites are limited to
the hemolymphatic system, treatment with the non-CNS pene-
trating drugs pentamidine (T. b. gambiense) or suramin (T. b.
rhodesiense) is effective. For the CNS form of the disease (stage 2),
patients are treated with the arsenic derivative melarsoprol or
eflornithine, which is only effective against the subspecies T. b.
gambiense [2]. Melarsoprol is particularly toxic because it causes
reactive encephalopathy in 5–10% of the patients, and 50% of
these patients die from this adverse reaction [3,4]. Incidence of
melarsoprol treatment failures of up to 25% have been reported in
endemic areas [3,5]. Prospects for vaccine development are very
limited [6]; therefore, chemotherapy remains the major compo-
nent of HAT control efforts. A safe oral drug that is effective
against both stage 1 and stage 2 HAT would eliminate the need for
disease staging and raise prospects of elimination of sleeping
sickness.
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develop new and effective treatments for HAT. In this report, we
describe discovery and characterization of the pharmacological
properties of 2,4-diaminopyrimidines against T. brucei. Original
2,4-diaminopyrimidine hits were identified from a high through-
put screening of SCYNEXIS proprietary libraries. This was
followed by hit-to-lead and lead optimization activities that
resulted in the discovery of the optimized lead SCYX-5070
described in this work. Related diaminopyrimidines have previ-
ously been described as potent and selective ATP competitive
inhibitors of human cyclin-dependent kinases (CDKs) for potential
treatment of cancer [7,8]. Here, we show that 2,4-diaminopyr-
imidines have a rapid time and concentration dependent cidal
activity against T. brucei in vitro and cure mice with the acute form
(stage 1) of trypanosomiasis. Activity was also demonstrated in vitro
against the related trypanosomatid protozoan parasites Leishmania
donovani and L. major. Because the activity of 2,4-diaminopyrimi-
dines versus T. brucei was discovered and optimized using
phenotypic screens, we have conducted studies to identify potential
molecular targets that may be responsible for the mechanism of
action against these parasites. Immobilized affinity approaches
have previously been used to identify targets of antiparastic
compounds [9–11]. Using a similar chemical proteomics approach
involving immobilized 2,4-diaminopyrimidine affinity chromatog-
raphy and mass spectrometry, we identified mitogen-activated
protein kinases (MAPKs) and cdc2-related kinases (CRKs) as
potential targets. Taken together, these findings suggest that
kinetoplastid kinases offer an attractive opportunity to develop safe
and effective therapy against HAT and leishmaniasis.
Materials and Methods
Ethics Statement
All animals used in this work were conventionally housed in
facilities accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care and were provided
food and water ad libitum. Animal studies were conducted in
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. Protocols for efficacy studies were approved by the
Institutional Animal Care and Use Committee of Pace University
(Animal Assurance Welfare Number: A3112-01). Surviving
animals were euthanized by carbon dioxide asphyxiation in sealed
containers as approved by the American Veterinary Association.
Protocols for infection and recovery in rats were approved by the
Institutional Animal Care and Use Committee of University of
North Carolina, Chapel Hill.
Parasites and cell culture
The bloodstream-form T. brucei brucei 427 strain was obtained
from Dr. Ken Stuart (Seattle Biomedical Research Institute,
Seattle, WA). Parasites were cultured in complete HMI-9 medium
[12] containing 10% FBS, 10% serum plus (SAFC Biosciences,
KS), 100 units penicillin and 0.1 mg/mL streptomycin and kept in
humidified incubators at 37uC and 5% CO2. Procyclic T. b. brucei
strain 29-13 was obtained from Dr. James Morris (Clemson
University, Clemson, SC) and cultured at 27uC with 5% CO2
using semi-defined medium (SDM-79) supplemented with 10%
FBS [13]. In vivo derived bloodstream-form T. b. brucei 427
parasites were isolated from adult female Wistar rats that were
infected by intraperitoneal injection with 1610
5 T. brucei obtained
from tissue culture. Rat blood was collected at peak parasitemia
(4–5 days post-infection) by cardiac puncture under terminal
anesthesia and parasites were recovered using DEAE cellulose
(Sigma-Aldrich, St. Louis, MO) anion-exchange columns as
previously described [14].
Promastigote stages of L. major (FV1 strain/MHOM/IL/80/
Friedlin) and L. donovani (LdBob strain/MHOM/SD/62/
1SCL2D) were provided by Dr. Stephen Beverley (Washington
University, St. Louis, MO). Leishmania promastigotes were cultured
at 26uC in M199 medium supplemented with 10% FCS [15,16].
Axenic amastigotes of L. donovani were generated by transforma-
tion from promastigotes at 37uC and low pH as previously
described [15,17]. To ensure log growth phase, protozoan
parasites were sub-cultured at appropriate dilutions (typically 1:
0–100) in fresh medium every 3–4 days. L929 mouse fibroblast
cells (ATCC CCL1) from American Type Culture Collection
(Rockville, MD) were used to determine parasite versus mamma-
lian cell selectivity. Fibroblasts were cultured in DMEM,
supplemented with 10% fetal bovine serum, 100 units penicillin
and 0.1 mg/mL streptomycin.
In vitro compound sensitivity assays
To prepare for assay, T. brucei and Leishmania spp. parasites in log
phase growth were counted and diluted to 2610
5/mL in their
specified media to generate a 2-fold working concentration for the
assay. Compounds to be tested were serially diluted in dimethyl
sulphoxide (DMSO) and 0.5 mL added to 50 mL media (triplicate)
in 96-well plates using a Biomek NX liquid handler (Beckman
Coulter, Fullerton, CA). Parasites from the diluted stock were
added to each well (50 mL) using a Multidrop 384 dispenser
(Thermo Electron Corporation) to give a final concentration of
1610
5/mL parasites, and the final DMSO concentration was
,0.5%. For evaluation of mammalian cell cytotoxicity, L929
fibroblasts were seeded at 2,000 cells/well and exposed to 2-fold
dilutions of test compounds directly parallel to the assay for
parasitic activity. Plates with parasites or L929 cells were
incubated with compounds under appropriate conditions for each
cell type. After 72 h of incubation, resazurin (Sigma-Aldrich, St.
Louis, MO; 20 mL of 12.5 mg/mL stock in phosphate buffered
saline) was added to each well and plates were incubated for an
additional 4–6 h. To assess cell viability, fluoroscence was read in
Author Summary
The protozoan parasite Trypanosoma brucei is the causa-
tive agent of human African trypanosomiasis (HAT) or
sleeping sickness, a fatal disease affecting nearly half a
million people in sub-Saharan Africa. Current treatments
for HAT have very poor safety profiles and are difficult to
administer. There is an urgent need for new, safe and
effective treatments for sleeping sickness. This work
describes the discovery of 2,4-diaminopyrimidines, exem-
plified by 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-
ylamino]-piperidine-1-carboxylic acid phenylamide or
SCYX-5070, as potent inhibitors of T. brucei growth in vitro
and also in animal models for HAT. To determine the
parasite proteins responsible for interaction with SCYX-
5070 and related compounds, affinity pull-downs were
performed followed by sequence analysis and parasite
genome database searching. The work revealed that
mitogen-activated protein kinases (MAPKs) and cdc2-
related kinases (CRKs) are the major proteins specifically
bound to the immobilized compound, suggesting their
potential participation in the pharmacological effects of
2,4-diaminopyrimidines against trypanosomatid protozoan
parasites. These data strongly support the use of 2,4-
diminipyrimidines as leads for the development of new
drug candidates for the treatment of HAT.
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excitation wavelength of 530 nm and emission of 590 nm.
Triplicate data points were averaged and XLfit software (fit model
205) from IDBS (Guilford, UK) was used to generate sigmoidal
dose-response curves for the determination of IC50 or IC90 values.
The minimum inhibitory concentration (MIC), defined as the
lowest concentration of compound that completely inhibits visible
parasite growth, was determined by visual inspection of 96-well
plates after 48–72 h of incubation with test compounds.
Time kill assays
Determination of compound-mediated killing of T. brucei in vitro
over time (i.e. time kill) was conducted using the CellTiter-Glo
reagent (Promega Inc., Madison, WI) to measure parasite ATP
content as a real time indicator of viability. Test compounds were
serially diluted into white-wall/clear-bottom 96-well plates (Corn-
ing Inc. Life Sciences, Lowell, MA) containing HMI-9 media
(50 mL/well) and parasites were added at a concentration of
2610
5/mL (50 mL/well) to duplicate plates for each evaluation
time point. At the selected time, 45 mL of CellTiter-Glo reagent
was added to a set of duplicate plates. The contents of the wells
were mixed to lyse the parasites and plates were incubated in the
dark for 10 min and read on the EnVision plate reader using a
luminescence protocol to measure cellular ATP content.
Tests for reversibility of trypanocidal effects
To establish the time required to cause persistent or irreversible
effects by test compounds, T. brucei parasites were assessed for their
ability to recover from transient exposure to test compounds.
Parasites were seeded in 96-well plates at 1610
6/mL (100 mL/
well) and incubated with serially diluted test compound. At the
desired time (exposure time) parasites were spun at 4,400 rpm for
5 min and the supernatant was aspirated to remove the
compound. The wash process was repeated two more times to
remove residual compound and parasites were incubated in drug-
free HMI-9 media. Following a 72 h incubation in drug free
medium, resazurin was added and parasite viability was
determined as described for the in vitro sensitivity assay.
Efficacy in mouse model for acute HAT
For efficacy studies against acute infections, groups of 3 female
Swiss Webster mice (Taconic Farms, Germantown, NY) were
injected intraperitoneally (i.p.) with infected rat blood containing
500 trypanosomes (T. b. brucei EATRO 110 strain). The infection
was allowed to progress for 24 hrs prior to treatment with test
compound given daily by bolus i.p. injection or oral gavage for 4
consecutive days. Test compounds were formulated in 20%
ethanol, 50% polyethylene glycol 400 and 30% carboxymethyl
cellulose and given at 200 mL for a 25 g animal. Animals were
monitored daily for signs of compound toxicity and clinical signs of
trypanosomiasis for a period of 30 days. After the end of the dosing
period, mice were checked for parasitemia twice a week by
microscopic examination of smears prepared from tail vein blood.
Animals remaining parasite free for more than 30 days beyond the
end of the treatment period were considered cured [18]. Control
untreated animals typically succumbed to the infection within 7–8
days following i.p. inoculation with parasites.
Compound synthesis and immobilization
All test compounds were synthesized and supplied by the
medicinal chemistry team at SCYNEXIS Inc. For compound
immobilization, epoxy activated Sepharose 6b (GE Healthcare,
Piscataway, NJ) (4.0 g, 19–40 m mol/gram) was washed with
distilled water (0.80 L); then moist beads were transferred to a
scintillation vial and suspended in DMF/water 1:1 (8.0 mL). A
solution of 4-[4-amino-5-(2-methoxy-benzoyl)-pyrimidin-2-yla-
mino]-piperidine-1-carboxylic acid (4-hydroxy-phenyl)-amide or
SCYX-7434 (11 mg, 6 mmol/gram beads) in DMF/water 1:1
(4.0 mL) was added to the suspension and pH adjusted to 11 with
aqueous NaOH [0.1]. The reaction was shaken at 40uC for 16 h
before a solution of ethanolamine (0.14 mL, 2.4 mmol) in DMF/
water 1:1 (2.4 mL) was added and allowed to shake at 40uC for an
additional 24 h. Compound-immobilized bead suspension was
filtered on a Buchner funnel and washed with DMF/water 1:1,
[0.1] aq. NaHCO3, [0.5] aq NaCl, [0.1] aq. NaCl (adjusted to
pH 8.0), [0.1] aq NaOAc and pH 4.0 aqueous buffer. The
remaining solid was suspended in pH 7.2 PBS buffer (2X volume
of solid). Control beads were generated by blocking reactive
groups by reaction with ethanolamine in DMF/water 1:1 at 40uC
with shaking for 24 h. Control beads were then filtered, washed
and resuspended as described above. Compound-immobilized or
control blocked sepharose beads were stored at 4uCas a 50% slurry
in phosphate buffer pH 7.4 containing 0.2% sodium azide.
Cell lysis, affinity chromatography and gel
electrophoresis
The protozoan parasites were cultured under conditions
described earlier, washed several times with phosphate buffered
saline, and the final pellets were stored at 280uC until protein
extraction and affinity association were performed. Procedures for
extract preparation and affinity chromatography were based on
work done previously by others [19,20] with some modifications.
Frozen parasite pellets were suspended in lysis buffer (LB)
containing 20 mM HEPES, pH 7.5, 50 mM NaCl, 0.25% NP-
40, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 10% glycerol and
Complete protease inhibitor cocktail (Roche Applied Science,
Indianapolis, IN). Protein concentrations were estimated based on
correlations with cell counts and protein measurements using the
Bio-Rad assay (Bio-Rad, Hercules, CA). Parasite pellets containing
0.5 mL/5 mg protein were sonicated while on ice with 265 sec
pulses on a Branson Sonifier 150 (Branson, Danbury, CT). Lysates
were centrifuged at 10,0006ga t4 uC, and supernatants were
recovered and pre-cleared for non-specific binding proteins by
incubation with blocked beads. To do this, control blocked beads
(100 mL/5 mg protein) were washed three times in LB, added to
the lysate and incubated at 4uC for 30 min with rotation. The
bead slurry containing lysates was centrifuged at 10,0006g, the
pre-cleared supernatant was removed and NaCl concentration
adjusted to 1 M in preparation for affinity association.
Just before use, compound-immobilized beads (100 mL/5 mg
protein) were washed 3 times with 1 mL pull-down buffer
consisting of LB +1M NaCl (PDB) and resuspended in 2 bead
volumes of the same buffer. Extract supernatant protein (3–5 mg
analytical or up to 100 mg preparative) was added to the beads
and incubated with rotation at 4uC for 45 min. The beads were
washed 3 times with 10 bead volumes of PDB by incubating with
rotation at 4uC for 5 min before each 10,0006g centrifugation
and removal of the supernatant to eliminate unbound proteins.
The wash procedure was repeated 3 additional times with LB.
Elution was done with the addition of 2 bead volumes of LB
supplemented with 0.56 mM SCYX-5070, 10 mM ATP and
20 mM MgCl2 with rotation at 4uC for 15 min. Proteins
remaining bound to the beads were eluted by boiling in 2X
Laemmli sample loading buffer. Aliquots of the total lysates and
the various eluted samples were resolved on 4–12% Bis-Tris
Criterion SDS-PAGE gels (Bio-Rad, Hercules, CA) and protein
detection was done by either silver staining using SilverXpress
Diaminopyrimidine Targets in Trypanosoma brucei
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staining (Bio-Rad, Hercules, CA) for preparative separations that
were followed by in-gel digestions for mass spectrometry analysis.
Sample preparation for mass spectrometry
Individual gel bands were manually excised and subjected to
overnight automated digestion with sequencing grade modified
trypsin (Promega, Madison, WI) on a ProGest Digestor (Genomic
Solutions, Ann Arbor, MI) at 37uC. Resultant peptides were
lyophilized and re-dissolved in 5 mL of 50% methanol/0.1%
trifluoroacetic acid (TFA). Peptides were spotted onto a MALDI
target plate with an equal volume of a-cyano-4-hydroxycinnamic
acid matrix solution and allowed to air dry.
Mass spectrometry
Mass spectrometry was carried out on a 4800 Plus MALDI
TOF/TOF Analyzer (Applied Biosystems, Foster City, CA).
Peptides were scanned in positive reflector mode over the mass
range 700–4000 m/z, with internal calibration against trypsin
peaks 842.51 and 2211.105 m/z. The 40 most intense peptides
were automatically selected for MS/MS analysis.
Protein identification by database search
Peptide mass and corresponding MS/MS fragmentation
information for each sample were searched against a database of
T. brucei (http://www.genedb.org/genedb/tryp/index.jsp) or L.
major (http://www.genedb.org/genedb/leish/) proteins using
Mascot (Marix Science, Boston, MA) and GPS Explorer (Applied
Biosystems, Foster City, CA). Proteins scoring above the Mascot
significance threshold were considered as positive identifications.
Results
Parasite inhibition in vitro
SCYX-5070 and the related analogue SCYX-1120 (Figure 1)
showed a dose-dependent killing of T. brucei in vitro as determined
from the reduction of the resazurin marker for cell viability
(Table 1). Blood stage and insect stage (procyclic) trypanosomes
showed equal sensitivity towards both compounds. SCYX-5070
exhibited 63-fold selective inhibition of parasite versus mammalian
cell (L929 mouse cell line) proliferation in vitro (Table 1). The
corresponding selectivity for the less potent analogue SCYX-1120
was 38-fold. Leishmania spp. were less susceptible to killing by 2,4-
diaminopyrimines, and the corresponding parasite versus host
selectivity was also lower compared to that observed with T. brucei
(Table 1). Dose-response curves generated from 2,4-diaminopyr-
imidine killing of T. brucei were relatively steep. For example, MIC
values, determined as concentration at which no visible growth
was observed after 72 h of exposure were 0.18 mM and 0.57 mM
for SCYX-5070 and SCYX-1120, respectively.
Time kill and tests for reversibility
Studies of time-dose response (time kill) of T. brucei following
exposure to SCYX-5070 are illustrated in Figure 2A. When
measured 24 h after exposure, the IC50 value for SCYX-5070
killing of T. brucei is very close to that measured in the standard
72 h assay (0.09 vs 0.07 mM). Time-dependent loss of viability of
Figure 1. Chemical structures of SCYX-5070 and SCYX-1120.
doi:10.1371/journal.pntd.0000956.g001
Table 1. Activity of 2,4-diaminopyrimidine compounds
against trypanosomatid protozoan parasites in vitro.
Cell/Parasite Parasite Stage SCYX-5070 SCYX-1120
T. brucei Blood Stage 0.0760.018 0.2860.02
T. brucei Procyclic 0.0760.007 0.5860.09
L. donovani Promastigote 1.9060.22 7.6361.43
L. major Promastigote 0.9960.38 5.5163.33
L. donovani Amastigote 1.1060.31 .10.81
L929 Fibroblast Mammalian Cell 7.0660.56 11.0960.63
Compound sensitivity for each cell type was determined using resazurin as an
indicator of viability following procedures described. Data are expressed as IC50
in mM and are averages from triplicate determinations.
doi:10.1371/journal.pntd.0000956.t001
Figure 2. Time-to-kill plots demonstrating concentration-
dependent and irreversibility of SCYX-5070 effects on T. b.
brucei in vitro. Parasite survival was measured at various times in the
presence on continuous drug (A) or after compound wash-out at
specified times and viability assessment at 72 h (B). Experiments were
conducted in triplicate and plots are mean survival of treated parasites
expressed as percentages of control untreated parasites.
doi:10.1371/journal.pntd.0000956.g002
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upon compound concentrations up to 0.69 mM or approximately
4 times the MIC. Concentrations of SCYX-5070 above 0.69 mM
did not result in faster or stronger killing of T. brucei in vitro
(Figure 2A). A similar concentration-dependent and MIC-
associated time-to-kill profile of T. brucei was observed for
SCYX-1120, in which killing was maximal at 2.29 mM or 4 times
the MIC (data not shown). Pulse incubation of T. brucei with
SCYX-5070 shows that 10–12 h of compound exposure at
concentrations above MIC is required to produce irreversible
effects on parasite survival (Figure 2B). Persistency or irreversibility
of SCYX-5070 effect is time and to a lesser degree, concentration
dependent. As observed for time kill experiments, increasing
concentration of compound far in excess of the measured MIC did
not lead to more robust or faster killing after wash-out and
incubation in compound-free medium. SCYX-1120 displayed
reversibility kinetics that were similar to those observed with
SCYX-5070-treated T. brucei parasites (data not shown).
SCYX-5070 cures acute trypanosomiasis in the mouse
model
The ability of SCYX-5070 to cure HAT in a mouse model was
assessed using female Swiss Webster mice inoculated i.p. with 500
T. brucei parasites. Untreated control animals succumbed to the
disease within 7–8 days following infection. SCYX-5070 admin-
istered i.p. twice daily at 20 mg/kg for 4 days starting 24 hours
post-infection produced 100% cure rates with no evidence of
compound related toxicity (Table 2). There was no dose related
toxicity observed even when SCYX-5070 was dosed to infected
animals at 50 mg/kg twice daily for 4 consecutive days (data not
shown). Given that the ultimate goal of the program is to identify
an orally active compound for the treatment of HAT, we also
assessed the potential efficacy of SCYX-5070 in the mouse model
following oral (p.o.) administration. SCYX-5070 cured all T. brucei
infected animals when given po twice daily for 4 consecutive days
(Table 2), suggesting good compound bioavailability.
Affinity purification and identification of protein targets
To generate an appropriate ligand for affinity immobilization,
an analogue of SCYX-5070 containing a hydroxyl, SCYX-7434,
was synthesized and coupled to ECH Sepharose (Figure 3). To
determine that the position used for immobilization does not result
in loss of activity, compound SCYX-1120 (Table 1) was
synthesized with an extended carbon linker off the phenyl ring.
SCYX-1120 retained significant in vitro activity against T. b. brucei
(Table 1), indicating that it retained SCYX-5070-like binding
properties. To identify potential protein targets that interact with
SCYX-5070 and related compounds, total extracts prepared from
T. brucei or Leishmania spp. were incubated with immobilized
SCYX-7434 or control capped sepharose beads. Following
extensive washing, the bound proteins were eluted with free
SCYX-5070 and ATP. Visualization of the eluted samples by
SDS-PAGE and silver staining showed several proteins, most
being in the 36–50 kD range (Figure 4, lanes 2–5). Most of the
proteins interact specifically with SCYX-7434-containing beads,
as indicated by the absence of significant staining in eluates from
capped beads (Figure 4, lanes 6–9). The affinity matrix interacts
with proteins of similar molecular sizes in procyclic (Figure 4, lane
4) and blood stream form T. brucei (Figure 4 lane 5), although there
are differences in the intensities of some bands. Similarly, the
major protein bands released with free compound and ATP from
affinity matrices loaded with extracts from promastigotes of L.
major (Figure 4, lane 3) and L. donovani (Figure 4, lane 2) were
similar with some minor exceptions. Collectively, the eluted
protein profile from association experiments suggests that the
immobilized 2,4-diaminipyrimidine is recognizing similar cellular
targets in trypanosomatid protozoans examined in these studies.
To identify potential protein targets for 2,4-diaminopyrimi-
dines, preparative amounts (up to 100 mg) of lysates from T. brucei
or L. major were incubated with immobilized SCYX-7434, eluted
with free compound and ATP followed by SDS-PAGE analysis. In
some instances, proteins that remained on the beads after the
initial elution were dissociated by boiling the beads in SDS-PAGE
loading buffer to provide sufficient material for downstream
protein analysis and identification work. Eluted proteins were
separated on SDS-PAGE gels and visualized by coomassie blue
staining. Protein bands were excised from the stained gel,
subjected to tryptic digestion and analysis by MALDI-TOF/
TOF spectrometry. A small aliquot from each of the preparative
elutions was retained for analysis on SDS-PAGE and silver
staining to provide a higher resolution image (Figure 5A and B) to
correlate with and aid in the interpretation of coomassie stained
bands that were subjected to MALDI-TOF/TOF analysis. A
comprehensive listing of all proteins that were positively identified
in this analysis is shown in Table S1. Table 3 shows the key target
proteins that are common to both T. brucei and L. major and they
include MAPKs, CRKs and other non-kinase proteins (Figure 5;
Table 3). MAPK2 and 9 were isolated from both T. brucei
(Figure 5A) and L. major (Figure 5B). In contrast, CRKs 1 and 6
were identified in T. brucei (Figure 5A) while CRK3 was identified
in L. major (Figure 5B). Surprisingly, each of the MAPK proteins
identified migrated as multiple bands on SDS-PAGE gels. This
was observed in samples obtained from both T. brucei and L. major
association experiments. Proteins eluted from samples prepared
from L. donovani were not subjected to MALDI-TOF/TOF
analysis as there is currently no genome database for this species
of Leishmania spp.
Table 2. Treatment of T. b. brucei acute mouse infections
a with SCYX-5070.
Tested Compound Dose
b (mg/kg) Dosing Route Cured
c/Total Ar. Survival (Days) % Cured
c
SCYX-5070 20 IP 3/3 .30 100
SCYX-5070 20 PO 3/3 .30 100
Pentamidine 2 IP 3/3 .30 100
Untreated 0 - 0/3 7 0
aMice were infected with 500 T. b. brucei EATRO 110 parasites and the infection was allowed to progress for 24 hrs prior to initiation of treatment. Parasitemia was
examined weekly and cures were determined as described in materials and methods.
bInfected animals were dosed twice daily for 4 consecutive days. Pentamidine was administered once daily for 4 days to serve as positive control.
cCured animals are defined as those that remained parasite free .30 days after the start of the dosing period.
doi:10.1371/journal.pntd.0000956.t002
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proteins identified, SCYX-7434 association experiments with T.
brucei extracts were conducted in the presence or absence of
varying concentrations of free SCYX-5070. The presence of
2.5 mM SCYX-5070 resulted in the loss of several bands
representing MAPK9 and 14 (Figure 6). When the concentration
of SCYX-5070 was increased to 40 mM in the association
experiments, MAPK 2 and CRK1 were no longer retained on
the beads (Figure 6). The association of immobilized SCYX-7434
with non-kinase proteins HSP70, tubulin, ribosomal proteins,
tryparedoxin peroxidase and cyclophilin A were not affected by
the presence of SCYX-5070 up to 40 mM. (Figure 6).
Discussion
Current HAT treatment regimens consist of pentamidine,
suramin, melarsoprol or eflornithine. The potential for effective
treatment of the disease using these drugs is very limited because
they are toxic or require cumbersome parenteral administration
[2–5]. With over 50 million people at risk of HAT in sub-Saharan
Africa, the need for a safe, effective and easily administered
treatment is crucial. Here we report that SCYX-5070 is a potent
inhibitor of T. brucei growth and exhibits good physicochemical
properties to serve as a lead for development of new drug
candidates for treatment of HAT. SCYX-5070 is a 2,4-
diaminopyrimidine related to a class of potent ATP competitive
inhibitors of mammalian CDKs, which have been explored as
potential treatments for cancer [7]. In this work, we demonstrate
that MAPKs and CRKs are the likely targets mediating the
mechanism of trypanocidal activity of SCYX-5070 and related
2,4-diaminopyrimidines. While several T. brucei kinases have been
indirectly implicated as essential enzymes, and thus potential drug
targets, we are not aware of examples of any small molecule kinase
inhibitors for the treatment of HAT or any other disease of
protozoan origin.
In vitro sensitivity assays showed potent trypanocidal activity of
SCYX-5070 and other related 2,4-diaminopyrimidines with
parasite versus host cell selectivity .60-fold. This level of
selectivity suggests a low potential for toxicity towards host cells
and provides an early indication of differences between parasite
versus mammalian target proteins. Closely related 2,4-diamino-
pyrimidines are known to target mammalian CDKs [7,8] while
another class of 2,4-diaminopyrimidines related to trimethoprim
was shown to target DHFR [21–23]. Interestingly, the different
life-cycle stages of both T. brucei and L. donovani displayed the same
level of sensitivity to 2,4-diaminopyrimidines reported in our
current work. This observation suggests that the molecular targets
through which SCYX-5070 exerts anti-parasitic effects are not
Figure 3. Chemical structure of free and immobilized 4-[4-Amino-5-(2-methoxy-benzoyl)-pyrimidin-2-ylamino]-piperidine-1-
carboxylic acid (4-hydroxy-phenyl)-amide (SCYX-7434). SCYX-7434 was coupled to activated sepharose 6B via the carbodiimide reaction, as
described in materials and methods. Control capped sepharose 6B was produced by the addition of ethanolamine to block the reactive groups.
doi:10.1371/journal.pntd.0000956.g003
Figure 4. Trypanosomatid protozoan proteins interacting with
immobilized diaminopyridine. Soluble extracts from different
stages of T. brucei and Leishmania spp. were loaded onto compound-
immobilized or control sepharose beads. Proteins bound to each matrix
were eluted and resolved on SDS-PAGE followed by visualization with
silver staining. Protein samples are: molecular weight markers (lane 1); L.
donovani promastigotes (lane 2, 6); L. major promastigotes (lane 3, 7); T.
brucei procyclics (lane 4, 8) and T. brucei blood stage (lane 5, 9).
doi:10.1371/journal.pntd.0000956.g004
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did not reveal a specific kinase or cell-cycle related effect. The
presence of potential targets in all stages of the parasites enabled us
to use the insect stages of Leishmania spp. (promastigotes) and T.
brucei (procyclics) for protein isolation since these stages are
relatively easy to culture and can provide large quantities of
protein required in the optimization of association experiments
with SCYX-7434.
Time kill studies with SCYX-5070 yielded a concentration- and
time-dependent decrease in ATP content or viability of T. brucei
blood stage parasites. Maximal trypanosome kill rates were
observed within 12–15 h following exposure of SCYX-5070 at
concentrations 4 times the MIC. These data suggest that 2,4-
diaminipyrimidines are primarily time-dependent trypanocidal
agents, the efficacy of which is only partly dependent on
concentration. Because the compounds are highly permeable,
the apparently saturable effects at high concentration suggest that
the target is limiting. In addition, P2 transporter knockout and
wild-type showed similar levels of sensitivity towards SCYX-5070.
Studies of the reversibility of trypanocidal effects revealed that
exposure of T. brucei to SCYX-5070 at concentrations 8–10-fold
above the MIC for 10–12 h results in elimination of parasites from
culture even after the compound has been washed out. The
inability of T. brucei parasites to recover from transient exposure to
compound in vitro suggests that 2,4-diaminopyrimidines are
retained within the parasites or that they exert irreversible effects
on the potential target(s) within the parasite during this time. This
rapid and irreversible kill rate and microscopic examinations
suggest that 2,4-diaminopyrimidines are cidal agents against T.
brucei. Encouraged by the potency and time-kill profile of SCYX-
5070 and related 2,4-diaminopyrimidines in vitro, studies were
conducted to determine the potential of this class of compounds to
cure animals infected with T. brucei. Cure (100%) of an acute T.
brucei infection in a mouse model was accomplished with a 4 day
regimen to complement the potency observed from in vitro
experiments. Efficacy in vivo against T. brucei suggests that
SCYX-5070 has sufficient stability and pharmacokinetics to
warrant further exploitation as a potential treatment for HAT.
Furthermore, SCYX-5070 did not exhibit toxic side effects when it
was administered to T. brucei infected mice at levels (50 mg/kg) far
in excess of what was required for full efficacy (20 mg/kg) in a 4-
day treatment regimen.
Although compounds from the 2,4-diaminopyrimidine class
related to SCYX-5070 are potent and selective inhibitors of
mammalian CDKs, we show that analogues selective for parasite
killing versus mammalian host can be developed. These
observations suggest the potential for different or novel targets in
parasitic protozoa. Using a chemical proteomics approach
involving immobilized compound affinity chromatography fol-
lowed by MALDI-TOF/TOF and database searching, we
identified T. brucei MAPKs and/or CRKs as the likely targets
mediating anti-parasitic activity of this class of kinase inhibitors in
protozoan parasites. This is in contrast to previous studies that
demonstrated that 2,4-diaminopyrirmidines closely related to
SCYX-5070 do not inhibit mammalian (human) MAPKs even
when tested up to 50 mM [8].
MAPKs from T. brucei and L. major were recovered as multiple
bands when association and pull-down experiments were con-
ducted with immobilized SCYX-7434 (Figure 5A and B). The
multiple banding phenomenon was not observed with CRKs or
other non-kinase proteins that were recovered from the affinity
matrix. This finding suggests that the multiple bands of MAPKs
Figure 5. Analysis and identification of proteins retained by immobilized SCYX-7434. Lysates from blood stage T. brucei or L. major were
loaded onto SCYX-7434-immobilized sepharose beads, eluted and analyzed on silver stained SDS-PAGE gels. (A) Bound T. brucei proteins were eluted
with SCYX-5070 and ATP (lane 1) or by boiling in sample buffer (lane 2). (B) L. major proteins bound to immobilized SCYX-7434 (lane 1) or capped
control beads (lane 2) were eluted with SCYX-5070 and ATP.
doi:10.1371/journal.pntd.0000956.g005
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parasite lysis and sample preparation. Analysis of all the identified
peptide fragments for the various affinity-purified MAPKs
revealed that fragments are the result of varying degrees of C-
terminus truncation that match the approximate band size
observed on the SDS-PAGE gels. A similar multiple banding of
MAPKs has been observed previously when Leishmania spp.
proteins were analyzed by tryptic digestion and mass spectrometry
(G. Spath, personal communication). In a recent study, a
proteomic analysis of procyclic T. brucei also noted that several
proteins were present in multiple variant forms [24]. This
phenomenon has been suggested as a potential mechanism that
enables the parasites to control activity of the protein in question.
The precise mechanism that leads to the generation of multiple
forms of MAPKs is unknown, but it seems to be a relatively
common observation on trypanosomatid proteins.
Various non-kinase proteins from T. brucei or L. major such as
tubulin, fructose aldolase, ribosomal proteins, cyclophilin, HSP70,
GAPDH and EF1-a were also observed to interact with the
SCYX-7434 affinity matrix. However, we and others suggest that
binding of these proteins is not specific to the 2,4-diaminopyr-
imidine or other kinase affinity ligands [25–27]. Some of these
proteins may also be associated with the matrix simply because
they are abundant within the extracts prepared from protozoan
parasites or other sources. For example, tubulin is a highly
abundant protein that also associates with SCYX-7434 affinity
matrix as well as the capped control beads, and this has been
observed in similar affinity work by others [25–27]. Other highly
expressed proteins that readily associate with affinity matrices used
in kinase isolations include HSP70, EF 1-a, GAPDH, ribosomal
proteins and fructose aldolase [16,24,25]. In our work, most of the
non-kinase proteins including cyclophilin and tryparedoxin
peroxidase remained bound to the SCYX-7434 affinity beads
when free SCYX-5070 was included in the association buffer. This
was in contrast to MAPKs and CRKs, which could be selectively
inhibited from the affinity matrix by excess free SCYX-5070,
suggesting a more specific interaction with immobilized SCYX-
7434.
To ensure that kinases were not associating with the SCYX-
7434 simply because of their relative abundance, we compared
gene expression levels for the MAPK and CRK family of proteins.
This was done by mining published data sets from T. brucei
genome wide expression studies [28,29]. From this analysis, we
determined that MAPK 2, 9 and 14 are in the lower to middle half
of expression levels of the MAPK family. Interestingly, MAPK 2 is
one of the lowest expressed members but it was one of the most
Table 3. Protein targets identified from T. brucei and L. major by LC/MS/MS.
aProtein # Name
bAccession
cMW (Da)
1 HSP70 (Heat-shock protein 70), MAPK14 Tb11.01.3110, Tb927.3.690 75320, 63787
2 MAPK14 Tb927.3.690 63787
3 MAPK14 Tb927.3.690 63787
4 Tubulin, a and b Tb927.1.2360, Tb927.1.2350 49755, 49672
5 MAPK2, EF-1a (Elongation factor 1-alpha) Tb10.70.2070, Tb10.70.5680 49710, 37784
6 MAPK2, MAPK14 Tb10.70.2070, Tb927.3.690 49710, 63787
7 MAPK2, MAPK9 Tb10.70.2070, Tb10.61.1850 49710, 42723
8 MAPK2, MAPK9 Tb10.70.2070, Tb10.61.1850 49710, 42723
9 MAPK2, MAPK9 Tb10.70.2070, Tb10.61.1850 49710, 42723
10 MAPK2, MAPK9, CRK6 Tb10.70.2070, Tb10.61.1850, Tb11.47.0031 49710, 42723, 36705
11 MAPK9, CRK6 Tb10.61.1850, Tb11.47.0031 42723, 36705
12 MAPkinase kinase kinase, CRK1 Tb01.61.1880, Tb10.70.7040 31355, 34329
13 MAPK9 Tb10.61.1850 42723
14 MAPK9, Tryparedoxin peroxidase Tb10.61.1850, Tb09.160.4280 42723, 22410
15 Cyclophilin A Tb11.03.0250 18705
16 HSP70 LmjF28.2780 71608
17 EF-1a LmjF17.0083, LmjF03.0820 49085
18 MPK2 LmjF36.0720 48309
19 MPK2 LmjF36.0720 48309
20 MPK2 LmjF36.0720 48309
21 MPK9, putative protein kinase LmjF19.0180, LmjF34.0030 44964, 44583
22 CRK3 LmjF36.0550 35622
23 Antigen gi|6531419 30016
24 40S Ribosomal protein S4 LmjF13.1230 30663
25 Tryparedoxin peroxidase LmjF15.1080 22114
26 Cyclophilin A LmjF25.0910 18811
aProtein number matches annotations in figure 5A and B.
bAccession numbers and
cmolecular weight obtained from genome databases.
doi:10.1371/journal.pntd.0000956.t003
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Examination of the CRK family in the genome expression
database indicates that CRK6 is highly expressed (compared to
other CRKs) in the bloodstream form of T. brucei and levels drop
about 3 fold in procyclics. Expression data for CKR1 was
divergent between the two studies relative to the other family
members. The significance of these expression levels is unclear
since the relation between mRNA and protein levels for these
specific kinases are unknown at present. Nevertheless, the
information on relative expression levels versus recovery from
association experiments could be valuable in prioritization of
targets for subsequent validation efforts.
The MAPKs identified in this work as potential targets for
SCYX-5070 are highly conserved eukaryotic proteins involved in
cellular processes such as proliferation, motility, cell-shape, stress
response, apoptosis and differentiation [30]. The trypanosomatid
protozoa Leishmania and Trypanosoma go through complex bio-
chemical and morphological changes during their life cycle, which
alternates between an insect vector and a mammalian host. The T.
brucei genome contains at least 13 MAPKs (MAPK 1–6; 9–15)
while Leishmania spp. has at least 15 (MAPK 1–15) [30]. In our
work, T. brucei MAPK 2, 9 and 14 were identified as targets of
association with SCYX-5070. Functional studies are not available
for any of the T. brucei MAPKs targeted by SCYX-5070 or related
2,4-diaminopyrimidines. In contrast, both MAPK targets of
SCYX-5070 in Leishmania, MAPK 2 and 9, have been shown to
be essential or play a role in the biology of the parasite [30]. For
example, MAPK 2 from L. mexicana is required to establish an
infection in the mouse model for leishmaniasis [30]. MAPK 9
deletion mutants have significantly elongated flagella and over-
expression has the opposite effect [31].
T. brucei has 11 CRKs (CRK1-4 and CRK6-12) most of which
seem to have evolved substantial parasite-specific features [32]. In
addition, 10 cyclins (CYC2-11) have been identified in T. brucei,
though very little is known about their pairings to CRKs except for
CRK 3, which interacts with CYC2 and CYC6 [33,34].
Trypanosomatid CRKs are phylogenetically related to CDKs
from various organisms, but most of them have insertions or other
modifications in their primary structure, suggestive of potential
novel mechanisms of regulation of activity [32]. Two of the three
CRKs (i.e. CRK 1 and CRK 3), identified as potential targets for
SCYX-5070 in this work, have been implicated as key regulators
of G1/S and G2/M checkpoint [35]. These observations involving
RNAi knockdowns show a complete block of cell growth or total
G2/M arrest only when knockdown of CRK 3 was paired with
that of another CRK (i.e. CRK 1, 2, 4 or 6). It is conceivable that
inhibition of multiple CRKs by SCYX-5070 is required for
maximal suppression of T. brucei growth or survival in vivo.
Chemical validation of CRK3 in Leishmania spp. was demonstrated
by screening of a chemical library against a recombinant L.
donovani CRK 3. The work identified 2,6,9-trisubstituted purines,
including the C-2-alkynylated purines, the indirubins, the
paullones and derivatives of the non-specific kinase inhibitor
staurosporine as some of the key hits [36]. Unfortunately, these
compounds lacked selectivity for parasite versus mammalian
CDKs and could not be exploited any further.
In summary, we have showed the activity of 2,4-diaminopyr-
imidines (SCYX-5070) against T. brucei growth in vitro. These
compounds also display robust activity in animal models of acute
HAT. We have used a proteomics approach to demonstrate
MAPKs and CRKs as potential targets mediating the mechanism
of action of SCYX-5070 and related compounds against
trypanosomatid protozoa. The effectiveness of 2,4-diaminopyr-
imidines as anti-trypanosome agents in vitro and in vivo provide a
potential good starting point for the development of a much
needed safe and effective new treatment for sleeping sickness.
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